Life Science Partner recruits former Senior Vice President, Sales and Marketing for Vermillion.
Life Science Partner announces the recruitment of Steve Lundy, a top commercial executive in early-stage diagnostics companies, to MicroPhage, an early-stage company based in Longmont, Colorado. Using its proprietary bacteriophage-based technology, MicroPhage is developing rapid assays for the direct identification and drug susceptibility of deadly bacterial strains such as Methicillin Resistant Staphylococcus Aureus (MRSA).
Most recently, Lundy was the Senior Vice President of Sales and Marketing for Vermillion, where he helped lead the company’s transformation from life sciences to a clinical diagnostics business model. Lundy previously served as Vice President of Sales, Marketing and Business Development for GeneOhm Sciences. He led the launch of the IDI-MRSA(TM) assay, the first nucleic-acid based test to be cleared by regulatory agencies to replace conventional microbiological culture by directly testing the clinical specimen. GeneOhm was acquired by BD (Becton, Dickinson and Company) in 2006.
“Lundy is a seasoned diagnostics industry leader who understands the market and the opportunity,” noted Tom Callaway, MD, President and Founder of Life Science Partner. “He brings an unsurpassed depth of experience in infectious disease diagnostics from GeneOhm to capitalize upon MicroPhage’s novel platform for MRSA detection.”
Lundy received his Bachelor of Science degree from the United States Air Force Academy in Colorado.